Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSURE: MesoPher in Combination With Surgery After Chemotherapy in Resectable Mesothelioma
NCT05304208Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2021
- Primary completion
- Dec 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MesoPher in malignant pleural mesothelioma (MPM), sponsored by Erasmus MC. Primary endpoint: Feasibility of completing (neo)adjuvant DCT and surgery at 2 years. Started Nov 2021; status: recruiting.
02
Drugs
MesoPher
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT05304208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304208.